Epoch-making Treatment with Transoral Robotic Surgery for Oropharyngeal Carcinoma
Transoral Robotic Surgery (TORS) was reported as being one of the most minimally
invasive surgery (MIS) procedures available by the University of Pennsylvania in
2005. TORS has increasingly been employed in the treatment of oropharyngeal carcinoma
throughout the world on account of the various advantages including superior surgical manipulation of the
oropharyngeal tissue, excellent visualization and accurate resection. We investigated 16 cases relating to
TORS and oropharyngeal carcinoma from a total of 78 English academic documents. We analyzed data from
595 patients who were treated with TORS from 2005 to 2013. Patient numbers of T1, T2, T3 and T4 were
243, 296, 38 and 18, respectively. The number of N0, N1, N2 and N3 were 168, 98,307 and 22, respectively.
The mean hospital stay time was 5.3 days. In regard to margin status, the margin free rate was 93.1%. The
percutaneous gastrostomy (PEG) tube dependency rate was 3.8%. Loco-regional recurrences and distant metastasis
were reported at 3.0% and 2.8%, respectively. The two year overall survival rate was 80.6-100%, and
2 year disease free survival rate was 92-100%. We conclude that TORS is a safe and advantageous procedure
for treating oropharyngeal carcinoma.
Keywords: Human papilloma virus (HPV), minimally invasive surgery (MIS), oropharyngeal carcinoma,
transoral robotic surgery (TORS).
Rights & PermissionsPrintExport